SEQENS announces the appointement of a new CEO
France-based SEQENS, a leader in the development and production of active pharmaceutical ingredients, pharmaceutical intermediates, and specialty ingredients, announces that Pascal Villemagne has been named Chief Executive Officer, effective 1st April 2025.
Pascal brings a wealth of experience to the role, having previously served as CEO of CARBOGEN AMCIS, a company specializing in the manufacture and development of custom APIs. During his tenure, he was instrumental in the transformation of CARBOGEN AMCIS, successfully leading structural changes and supporting the organization’s digital transformation. His leadership enabled the company to achieve significant growth, notably through expansion into new markets and the strengthening of its areas of expertise.
Prior to his tenure at CARBOGEN AMCIS, Pascal cultivated a career within the life sciences sector, holding a number of senior commercial and operational leadership positions. His experience encompasses roles such as Vice President, Contract Manufacturing, at Farmhispania, a Spanish API contract manufacturing organization, and Sales and Business Development Manager at both Inabata and Cambrex. Earlier in his career, he served as Raw Material Purchasing Manager at Sanofi.
Pascal commented, “I am thrilled to join SEQENS as its next CEO and excited to collaborate with SK Capital to drive the company’s future success. SEQENS’ strong, technology-driven product portfolio has established it as a true market leader, and I am particularly drawn to the company’s commitment to these vital markets. I believe SEQENS is uniquely positioned to provide exceptional value to its customers through cost-effective, sustainable solutions and best-in-class quality. The strategic investments in technology and capacity under SK Capital’s ownership have created a powerful platform for SEQENS to continue exceeding customer expectations.”
Aaron Davenport, Managing Director at SK Capital, commented, “We are thrilled to welcome Pascal, who we believe is uniquely positioned to lead SEQENS in its next chapter, bringing a track record of successful leadership in the pharmaceutical services industry. I would also like to thank Pierre Luzeau for his leadership and partnership with SK Capital, and I am truly excited for his next phase with the Company.”
Pierre Luzeau has served as the CEO of SEQENS since 2006 and is joining the Supervisory Board as an Independent Director and Chairman of the SEQENS CSR Committee. In this role, he will continue to provide insight and direction following his successful growth and development of SEQENS. Pierre commented :”I feel privileged to have led the SEQENS team over the past twenty years, since the creation of the group. Pascal will bring his experience as an executive with a track record in many different companies as well as an in-depth knowledge of the pharmaceutical sector where SEQENS aims to grow, building on the acquisition of CellforCure at the end of 2023. We are looking forward to a seamless transition, and I am thrilled to continue to support SEQENS as a member of the Supervisory Board.”